Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCVHIV Can Be Prevented— Are You Doing Your Part?
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.
Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.
Colasanti J, et al. Open Forum Infect Dis. 2018;5(6):ofy104.
Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295
Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.
Huang YA, et al. MMWR Morb Mortal Wkly Rep. 2018;67(41):1147-1150.
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM, et al. Lancet HIV. 2017;4(9):e402-e410.
Rolle CP, et al. J Acquir Immun Defic Syndr. 2017;76(3):250-258.
Willingness to use pre-exposure prophylaxis among black and white men who have sex with men in Atlanta, Georgia.
Rolle CP, et al. Int J STD AIDS. 2017;28(9):849-857.
Are you PrEP’d to Discuss Sexual Health & HIV Prevention?
This innovative live activity is designed for PCPs to practice their skills in sexual health discussions and HIV prevention via a simulated tele-visit with a standardized patient, trained to simulate the signs, symptoms, and behaviors of patients seen in daily practice. Earn 0.5 CME/CE credit. Click here for more information!
HIV Can Be Prevented— Are You Doing Your Part?
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies